Wide Ranks

INSM

Insmed Incorporated

75.88

Top Statistics
Market Cap 13 B Forward PE -18.59 Revenue Growth 18.20 %
Current Ratio 6.37 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -252.01 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -19.09 Enterprise / Revenue 38.68 Price To Sales Trailing12 Months 39.58
Profitability
Profit Margins -252.01 % Operating Margins -212.73 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 8.21 Total Debt 1 B
Total Debt To Equity 239.94 Current Ratio 6.37 Book Value Per Share 2.70
All Measures
Short Ratio 880.00 % Message Board Id finmb_29978 Shares Short Prior Month 13 M
Return On Equity -8.91 City Bridgewater Uuid c5250e99-b287-307b-8d73-594ed03cb1d9
Previous Close 75.68 First Trade Date Epoch Utc 959 M Book Value 2.70
Beta 1.12 Total Debt 1 B Volume 934539
Price To Book 28.07 Last Split Date 1 B Fifty Two Week Low 21.92
Total Cash Per Share 8.21 Total Revenue 342 M Shares Short Previous Month Date 1 B
Target Median Price 88.00 Max Age 86400 Recommendation Mean 1.33
Sand P52 Week Change 0.3133 Operating Margins -212.73 % Target Mean Price 89.40
Net Income To Common -864284992 Short Percent Of Float 0.0685 Implied Shares Outstanding 178 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 1 B Next Fiscal Year End 1 B
Revenue Per Share 2.21 Held Percent Insiders 0.0091 Ebitda Margins -202.67 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 75.68 Target Low Price 75.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 72.16 Open 75.78 Free Cashflow -378847872
State NJ Dividend Yield 0.00 % Return On Assets -0.2605
Time Zone Short Name EST Trailing Eps -5.55 Day Low 74.79
Address1 700 US Highway 202/206 Shares Outstanding 178 M Price Hint 2
Target High Price 105.00 Website https://www.insmed.com 52 Week Change 2.03
Average Volume 1 M Forward Eps -4.23 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 582.70 % Last Split Factor 1:10
Regular Market Day High 76.64 Is_sp_500 False Profit Margins -252.01 %
Debt To Equity 239.94 Fifty Two Week High 80.53 Day High 76.64
Shares Short 12 M Regular Market Open 75.78 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 38.68 Revenue Growth 18.20 %
Shares Percent Shares Out 0.0676 Operating Cashflow -618721984 Currency USD
Time Zone Full Name America/New_York Market Cap 13 B Is_nasdaq_100 False
Zip 08807 Quote Type EQUITY Industry Biotechnology
Long Name Insmed Incorporated Regular Market Day Low 74.79 Held Percent Institutions 1.11
Current Price 75.88 Enterprise To Ebitda -19.09 Financial Currency USD
Current Ratio 6.37 Gross Margins 77.25 % Industry Disp Biotechnology
Number Of Analyst Opinions 17 Country United States Float Shares 167 M
Two Hundred Day Average 55.22 Ir Website http://investor.insmed.com/stockquote.cfm Enterprise Value 13 B
Price To Sales Trailing12 Months 39.58 Forward PE -18.59 Regular Market Volume 934539
Ebitda -695056000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.

It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.

The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.